Relmada Plans Phase 2 Results Presentation for NDV-01, Advances Sepranolone Development

Relmada Therapeutics has shifted its focus from its lead candidate, esmethadone (REL-1017), after disappointing interim results in treating Major Depressive Disorder, opting instead to advance new drug candidates NDV-01 and Sepranolone. NDV-01 is currently undergoing Phase 2 trials for non-muscle-invasive bladder cancer, while Sepranolone is being developed for various neurodevelopmental disorders. The company reported a net loss of approximately $79.98 million for 2024, with total operating expenses decreasing from the previous year, but it continues to face significant liquidity challenges, raising doubts about its ability to sustain operations without additional funding. Relmada is exploring financing options, including the sale of equity or debt securities. Notably, the company is set to report its fourth-quarter financial results on March 27, 2025, where it will discuss its recent progress and future plans. As of the latest reports, Relmada's stock trades on the Nasdaq under the ticker symbol RLMD, with a current market capitalization of approximately $5.36 million.